This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pedersen, M. G.
Right arrow Articles by Olsen, K. E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pedersen, M. G.
Right arrow Articles by Olsen, K. E. P.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2008, p. 2987-2991, Vol. 46, No. 9
0095-1137/08/$08.00+0     doi:10.1128/JCM.00871-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Subtype-Specific Suppression of Shiga Toxin 2 Released from Escherichia coli upon Exposure to Protein Synthesis Inhibitors {triangledown}

Malene Gantzhorn Pedersen,1 Claus Hansen,1,{dagger} Erik Riise,2 Søren Persson,1 and Katharina E. P. Olsen1*

Department of Bacteriology, Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark,1 Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark2

Received 6 May 2008/ Returned for modification 22 June 2008/ Accepted 14 July 2008

Shiga toxins (Stx) are important virulence factors in the pathogenesis of severe disease including hemolytic-uremic syndrome, caused by Stx-producing Escherichia coli (STEC). STEC strains increase the release of Stx in vitro following the addition of fluoroquinolones, whereas protein synthesis inhibitors previously have been reported to suppress the release of Stx. The amount of Stx released from wild-type STEC strains incubated with protein synthesis inhibitors was examined by a Vero cell cytotoxicity assay. The amounts released were compared to the Stx type (Stx1 or Stx2) and additionally to the individual subtypes and toxin variants of Stx2. In general, Stx2 release was suppressed significantly upon exposure to protein synthesis inhibitors at MICs, which was not observed in the case of Stx1. Also, the average amount of different Stx2 toxin variants released was suppressed to various levels ranging from 14.0% (Stx2-O157-EDL933) to 94.7% (Stx2d-O8-C466-01B). Clinical studies exploring protein synthesis inhibitors as future candidates for treatment of intestinal infections caused by Stx2-producing STEC should therefore include knowledge of the toxin variant in addition to the subtype.

* Corresponding author. Mailing address: The National Reference Laboratory for Enteropathogenic Bacteria, Department of Bacteriology, Mycology and Parasitology, Division of Microbiology and Diagnostics, Statens Serum Institut, Artillerivej 5, Building 211, Room 132, DK-2300 Copenhagen S, Denmark. Phone: 45 32688423. Fax: 45 32688130. E-mail: keo{at}ssi.dk

{triangledown} Published ahead of print on 23 July 2008.

{dagger} Present address: Department of Pharmaceutics and Analytical Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark.

Journal of Clinical Microbiology, September 2008, p. 2987-2991, Vol. 46, No. 9
0095-1137/08/$08.00+0     doi:10.1128/JCM.00871-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»